Interest in wavefront analysis has been growing worldwide. Koh et al.
36 quantified the optical impact of tear film breakup for the first time using a wavefront sensor from Japan. This study confirmed that physicians need to perform careful preoperative wavefront measurements before refractive surgery to avoid the effects of tear film breakup.
The introduction of sequential measurements of corneal wavefront aberration allowed the postblink changes in HOA to be quantified over time.
25,26 This, in turn, led to a better understanding of how the tear film influences QoV. Koh and colleagues (Koh et al.,
37–40 Mihashi et al.,
41 and Hirohara et al.
42) specifically examined sequential ocular wavefront aberrations and the optical effect of tear film dynamics after blinking. They introduced the following quantitative indices that describe sequential HOA change over time: the total HOA fluctuation index (FI) and stability index (SI). Both FI and SI are useful in describing time-dependent HOA changes that cannot be detected with a single measurement.
37 FI and SI measurements can now be performed in the clinical setting, because the Hartmann-Shack wavefront aberrometer developed in their study was used as the prototype for the commercially available KR-1W (Topcon Corp., Tokyo, Japan).
Wavefront analysis studies in Japan have played a significant role in understanding the mechanisms underlying visual disturbances associated with dry eye.
4 Total ocular HOAs are believed to be stable between blinks in normal eyes (
Fig. 2A), but evidence shows that, even in clinically normal subjects, HOAs can change dynamically after blinking.
37 Subjects with a decreased tear film BUT and dry eye symptoms, but without ocular surface damage or tear deficiency, are designated as having “short BUT dry eye.” In these eyes, HOAs increase over time after blinking, and continue to increase during the 10-second measurement period, during which the subject does not blink (
Fig. 2B).
39 In contrast, subjects with “aqueous tear-deficient” dry eye showed high initial total ocular HOAs, and dry eyes with superficial punctate keratopathy (SPK) of the central cornea had even higher initial HOAs (
Fig. 2C).
40 Interestingly, dry eyes without SPK in the central corneal region had consistently lower total HOAs, which exhibited similar changes over time relative to those seen in normal eyes
40 (
Fig. 2 in Ref.
4). These findings were confirmed by Kaido et al.,
43 who reported that optical disturbances in the central optical zone of corneas with dry eye may affect visual performance. This is particularly true in short BUT dry eye, which often has an underestimated impact. In short BUT dry eye, patients often complain of severe dry eye symptoms, particularly ocular fatigue.
44 Functional visual acuity and sequential wavefront measurements have helped physicians better understand the importance of treating short BUT dry eye.
45,46
Two unique topical pharmacologic agents for treating dry eye are commercially available in Japan. Diquafosol ophthalmic solution 3% (Diquas, ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan) stimulates aqueous and mucous secretions directly on the ocular surface. Rebamipide ophthalmic suspension 2% (Mucosta ophthalmic suspension UD2%; Otsuka Pharmaceutical, Co., Ltd, Tokyo, Japan) stimulates mucous secretion. The long-term use of diquafosol in eyes with aqueous-deficient dry eye has been shown to reduce HOAs, improve tear film stability, and decrease corneal epithelial damage.
47 Diquafosol treatment also significantly improved ocular HOAs in eyes with short BUT dry eye.
48 Rebamipide improved optical quality in the short BUT type; after treatment, a decrease was observed in the “progressive increase pattern” of the dynamic HOAs. Eyes with short BUT dry eye showed improvement in both optical quality and tear film BUT (measured with fluorescein).
49